PARIS, March 24, 2010 /PRNewswire/ -- Boston Scientific Corporation today announced European commercial availability of the Company's new cardiac rhythm management connector system, which consists of the ENDOTAK RELIANCE(R) 4-SITE defibrillation lead and compatible COGNIS(R) cardiac resynchronization therapy defibrillators (CRT-Ds) and TELIGEN(R) implantable cardioverter defibrillators (ICDs). The system is designed to simplify the implant procedure by combining three terminals into one integrated connector, further reducing the volume of the world's smallest and thinnest high-energy CRT-Ds and ICDs. The Company announced CE Mark and first implant of this system in May 2009.

Boston Scientific commissioned a prospective, multi-center observational clinical study involving more than 400 patients to extensively evaluate the 4-SITE system and to demonstrate appropriate clinical performance before making it broadly available in Europe, said Poul Erik Bloch Thomsen, M.D., Ph.D., Gentofte University Hospital, Copenhagen, Denmark. The study examined both shocking and pacing performances and showed that the 4-SITE system increased the simplicity and overall efficiency of the implant procedure, and further reduced the already low likelihood of complications arising from connections being reversed.

The launch of the ENDOTAK RELIANCE 4-SITE lead system is another significant milestone for our Company, which spans from the first human implant of the ICD 30 years ago to manufacturing the smallest, thinnest high energy devices today, said Fred Hrkac, President of Europe, Middle East and Africa (EMEA) for Boston Scientific. This system represents the next advance for the ENDOTAK RELIANCE lead family, which has demonstrated reliability in more than 400,000 implants worldwide.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like anticipate, expect, project, believe, plan, estimate, intend and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

SOURCE: Boston Scientific Corporation

CONTACT: CONTACT: Geraldine Varoqui, Director International PublicRelation, Tel: +49-2102-489-461, Mob: +49-170-782-85-58, varoquig@bsci.com